Key Drivers
- Gross Strength
- Cash Burn
- Rich Valuation
AIAI Summary
ADPT is increasingly a focused MRD diagnostics growth story with strong gross margins and real commercial traction, but the stock now hinges on proving that revenue can keep accelerating into operating leverage while avoiding renewed cash burn and dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Strength
- •Cash Burn
- •Rich Valuation
ADPT has strong gross margins and liquidity, but persistent operating losses, negative cash flow, and a rich 12.7x sales valuation make the stock look risky and expensive.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Near resistance
- •Volatile pullbacks
ADPT has trended higher over the last month with higher lows and a test of resistance near $25.25–$25.45, but the move remains volatile and needs support around $24.45–$24.60 to hold for continuation.
Sharp reversals on several recent sessions signal elevated short-term volatility
Sentiment & News
Key News Insights:
- •MRD Acceleration
- •Margin Expansion
- •Stake Reductions
Adaptive Biotechnologies delivered a strong Q2 beat with faster MRD growth, improved margins, a higher full-year outlook, and progress toward a pure-play MRD diagnostics model, though some institutional investors trimmed stakes.
The news is positive for ADPT overall, but mixed institutional selling suggests the stock may need continued execution to sustain its momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings